| CTA gene of interest |
No. of samples tested |
Matched normal tissue tested? |
% Expression in cell lines
(number of positive cell line expression/number of cell lines tested) |
Comments |
| ADAM-2 |
29 [94,114] |
No |
|
ADAM-2 also referred to as CT15 |
| CT9 |
6 [139] |
No |
|
CT9 referred to as bromodomain testis-specific gene (BRDT) |
| CT17 |
9 [114] |
No |
|
|
| CT47 |
6 [140] |
No |
(3/3) 100% [140] |
Not certain from text if CT47 expression detected in all three cell lines. Quantitative PCR and relative expression to testis used to decide if not expressed in tumour tissue. |
| FTHL17 |
11 [90] |
No |
|
|
| GAGE-1 to GAGE-8 |
34 [55] |
Yes |
|
Eight GAGE family members tested (i.e. GAGE-1-8) |
| KU-CT-1 |
21 [72] |
No |
(0/7) 0% [72] |
Note: 1 out of 18 patients (5.6%) had a positive serological test |
| MORC |
20 [94] |
No |
|
|
| MMA-1A |
5 [141] |
No |
(1/8) 12.5% [141] |
Weak expression in cell lines only |
| MMA-1B |
5 [141] |
No |
(2/8) 25% [141] |
Weak expression in cell lines only |
| PAGE-1 |
34 [55] |
Yes |
|
|
| RAGE-4 |
34 [55] |
Yes |
|
|
| SAGE |
19 [119] |
No |
|
|
| SCAGE-ac |
34 [55] |
Yes |
|
|
| SGY-1 |
20 [94] |
No |
|
|
| SPO11 |
20 [94] |
No |
|
|
| TAF2Q |
11 [90] |
No |
|
|
| TDRD1 |
8 [90] |
No |
|
|
| TEX15 |
8 [90] |
No |
|
Expressed in normal brain tissue |
| TPX-1 |
20 [94] |
No |
|
|
